Tenofovir bests entecavir for HCC protection in hepatitis B
In patients with chronic hepatitis B, tenofovir disoproxil fumarate appears to perform better than entecavir at reducing the risk of hepatocellular carcinoma (HCC) as well as improving survival, especially among those who are naïve to treatment and with underlying cirrhosis, as reported in a study.
